Drug application
NEOSTIGMINE METHYLSULFATE (NEOSTIGMINE METHYLSULFATE)
Drugs@FDA ANDA 212627 · NIVAGEN
Key facts
| Drug name | NEOSTIGMINE METHYLSULFATE |
|---|---|
| Active ingredients | NEOSTIGMINE METHYLSULFATE |
| Application type | ANDA |
| Application number | 212627 |
| Company | NIVAGEN |
| Dosage forms | SOLUTION, INTRAVENOUS |
| Strength | 5MG/10ML (0.5MG/ML) |
| Marketing status | Prescription |
| TE codes | AP |
| Reference listed drug | No |
| Latest submission status date | Nov 3, 2022 |
At a glance
- 1–9 Submissions
- None Label versions
- 1–9 Products
- 10–99 Therapeutic equivalents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.